Immunomodulatory treatment with systemic GM-CSF augments pulmonary immune responses and improves neurological outcome after experimental stroke.

ABSTRACT

Stroke-induced immunodepression is an independent risk factor for stroke-associated pneumonia (SAP). Granulocyte-macrophage colony stimulating factor (GM-CSF) has neuroprotective properties in experimental stroke and been demonstrated to reverse immunodepression in sepsis patients. However, whether GM-CSF restores immune function after stroke preventing SAP and improving outcome is unknown. Here, we demonstrated that GM-CSF treatment improved peripheral and pulmonary leukocyte numbers, peripheral cytokine responses, lowered lung bacterial burden in the early course and improved long-term functional outcome after experimental stroke. These data suggest that GM-CSF is promising for stroke treatment since it not only acts neuroprotective in the ischemic brain but may also protect against detrimental post-stroke infections.